Business
Taysha Gene Therapies Announces Two Poster Presentations on TSHA-102 in Rett Syndrome at Upcoming European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress
DALLAS, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and
About this update from Taysha Gene Therapies, Inc.
[{"type":"text","content":"DALLAS, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today announced that it will present data on its TSHA-102 program in evaluation for Rett syndrome during two poster presentations at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress, taking place in Brussels, Belgium from October 24-27, 2023. TSHA-102 is a self-complementary intrathecally delivered AAV9 investigational gene transfer therapy that utilizes a novel miRNA-Responsive Auto-Regulatory Element (miRARE) technology designed to mediate levels of MECP2 in the CNS on a cell-by-cell basis without risk of overexpression. The Company will present new preclinical in vitro data supporting the miRARE technology, as well as initial clinical data from the first adult patient dosed with TSHA-102 in the REVEAL Phase 1/2 adult trial. Poster presentation details are as follows: Abstract Title: The microRNA-responsive autoregulatory element from TSHA-102 for Rett Syndrome modulates therapeutic transgene expression in response to cellular MECP2 in mouse and human cell lines Presenters: Emdadul Haque, Ph.D., Director, Translational Sciences, and Fred Porter, Ph.D., Chief of Staff and Technical Operations Officer, Taysha Gene TherapiesPoster Session Date/Time: Wednesday, October 25 at 17:00-18:15 CET and Thursday, October 26 at 20:30-21:30 CETPoster Session: CNS & Sensory DiseasesPoster Number: P435 Abstract Title: Early safety and efficacy observations following the first use of TSHA-102 gene therapy in a patient with Rett SyndromePresenter: Benit Maru, MBChB, Ph.D., Chief Medical Officer and Head of Clinical Development, Taysha Gene TherapiesPoster Session Date/Time: Wednesday, October 25 at 18:15-19:30 CET and Thursday, October 26 at 19:30-20:30 CETPoster Session: Accessibility of Gene TherapyPoster Number: P302 Additional details on the meeting can be found at the ESGCT 30th Annual Congress website. About TSHA-102TSHA-102 is a self-complementary intrathecally delivered AAV9 investigational gene transfer therapy in clinical evaluation for Rett syndrome. TSHA-102 utilizes a novel miRNA-Responsive Auto-Regulatory Element (miRARE) technology designed to ...